Compugen Analyst Ratings
Compugen Analyst Ratings
While ratings are subjective and will change, the latest Compugen (CGEN) rating was a reiterated with a price target of $0.00 to $13.00. The current price Compugen (CGEN) is trading at is $1.03, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 1162.14% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 06/06/2023 | 1162.14% | EF Hutton | → $13 | Reiterates | → Buy |
| 05/26/2023 | 1162.14% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 05/24/2023 | 1162.14% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 05/16/2023 | 579.61% | Oppenheimer | $8 → $7 | Maintains | Outperform |
| 02/28/2023 | 676.7% | Oppenheimer | → $8 | Reiterates | → Outperform |
| 02/08/2023 | -51.46% | Jefferies | → $0.5 | Downgrades | Hold → Underperform |
| 01/05/2023 | 1162.14% | EF Hutton | → $13 | Initiates Coverage On | → Buy |
| 11/15/2022 | 676.7% | Oppenheimer | $12 → $8 | Maintains | Outperform |
| 08/23/2022 | 288.35% | Truist Securities | $14 → $4 | Maintains | Buy |
| 08/08/2022 | 288.35% | JMP Securities | $8 → $4 | Maintains | Market Outperform |
| 08/08/2022 | 1065.05% | Oppenheimer | $14 → $12 | Maintains | Outperform |
| 08/05/2022 | 94.17% | Jefferies | → $2 | Downgrades | Buy → Hold |
| 02/25/2022 | 1259.22% | Oppenheimer | $17 → $14 | Maintains | Outperform |
| 02/25/2022 | 773.79% | SVB Leerink | $16 → $9 | Maintains | Outperform |
| 04/06/2021 | 1453.4% | SVB Leerink | $19 → $16 | Maintains | Outperform |
| 08/19/2020 | 1744.66% | SVB Leerink | $15 → $19 | Maintains | Outperform |
| 05/13/2020 | 1744.66% | Stifel | → $19 | Initiates Coverage On | → Buy |
| 05/07/2020 | 1356.31% | SVB Leerink | → $15 | Initiates Coverage On | → Outperform |
| 04/22/2020 | 2618.45% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 03/24/2020 | 1453.4% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/21/2020 | 1162.14% | Cantor Fitzgerald | $10 → $13 | Reiterates | → Overweight |
| 01/16/2020 | 870.87% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/07/2023 | 1162.14% | EF Hutton | →$13 | 重申 | 购买→购买 |
| 06/06/2023 | 1162.14% | EF Hutton | →$13 | 重申 | →购买 |
| 2023年05月26日 | 1162.14% | EF Hutton | →$13 | 重申 | 购买→购买 |
| 2023年05月24日 | 1162.14% | EF Hutton | →$13 | 重申 | 购买→购买 |
| 2023年05月16日 | 579.61% | 奥本海默 | $8→$7 | 维护 | 跑赢大盘 |
| 02/28/2023 | 676.7% | 奥本海默 | →$8 | 重申 | →跑赢大盘 |
| 02/08/2023 | -51.46% | 杰富瑞 | →$0.5 | 评级下调 | 持有→表现不佳 |
| 01/05/2023 | 1162.14% | EF Hutton | →$13 | 开始承保 | →购买 |
| 2022年11月15日 | 676.7% | 奥本海默 | $12→$8 | 维护 | 跑赢大盘 |
| 2022年08月23日 | 288.35% | Truist证券 | $14→$4 | 维护 | 买 |
| 2022/08/08 | 288.35% | JMP证券 | $8→$4 | 维护 | 市场表现强于大盘 |
| 2022/08/08 | 1065.05% | 奥本海默 | $14→$12 | 维护 | 跑赢大盘 |
| 08/05/2022 | 94.17% | 杰富瑞 | →$2 | 评级下调 | 购买→Hold |
| 02/25/2022 | 1259.22% | 奥本海默 | $17→$14 | 维护 | 跑赢大盘 |
| 02/25/2022 | 773.79% | SVB Leerink | $16→$9 | 维护 | 跑赢大盘 |
| 04/06/2021 | 1453.4% | SVB Leerink | $19→$16 | 维护 | 跑赢大盘 |
| 2020年08月19日 | 1744.66% | SVB Leerink | $15→$19 | 维护 | 跑赢大盘 |
| 2020/05/13 | 1744.66% | Stifel | →$19 | 开始承保 | →购买 |
| 05/07/2020 | 1356.31% | SVB Leerink | →$15 | 开始承保 | →跑赢大盘 |
| 04/22/2020 | 2618.45% | 罗斯资本 | →$28 | 开始承保 | →购买 |
| 03/24/2020 | 1453.4% | SunTrust Robinson Humphrey | →$16 | 开始承保 | →购买 |
| 02/21/2020 | 1162.14% | 康托·菲茨杰拉德 | $10→$13 | 重申 | →超重 |
| 1/16/2020 | 870.87% | 康托·菲茨杰拉德 | →$10 | 开始承保 | →超重 |
What is the target price for Compugen (CGEN)?
康柏(Compugen)的目标价是多少？
The latest price target for Compugen (NASDAQ: CGEN) was reported by EF Hutton on August 7, 2023. The analyst firm set a price target for $13.00 expecting CGEN to rise to within 12 months (a possible 1162.14% upside). 12 analyst firms have reported ratings in the last year.
英孚赫顿于2023年8月7日报道了康柏基因(纳斯达克代码：CGEN)的最新目标价。这家分析公司将目标价定为13美元，预计CGEN将在12个月内上涨至(可能上涨1162.14%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Compugen (CGEN)?
Compugen(CGEN)的最新分析师评级是多少？
The latest analyst rating for Compugen (NASDAQ: CGEN) was provided by EF Hutton, and Compugen reiterated their buy rating.
科尔根(纳斯达克代码：CGEN)的最新分析师评级由EF Hutton提供，科尔根重申其买入评级。
When is the next analyst rating going to be posted or updated for Compugen (CGEN)?
Compugen(CGEN)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Compugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Compugen was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Compugen的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Compugen的上一次评级是在2023年8月7日提交的，所以你应该预计下一次评级将在2024年8月7日左右提供。
Is the Analyst Rating Compugen (CGEN) correct?
分析师评级计算(CGEN)正确吗？
While ratings are subjective and will change, the latest Compugen (CGEN) rating was a reiterated with a price target of $0.00 to $13.00. The current price Compugen (CGEN) is trading at is $1.03, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Compugen(CGEN)评级被重申，目标价在0.00美元至13.00美元之间。Compugen目前的交易价格为1.03美元，在分析师的预测范围内。
